mTOR Inhibitor Therapy

mTOR Inhibitor Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">mTOR Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>ALS</td>
</tr>
</table>

[mTOR](/mechanisms/mtor-signaling-pathway) (mechanistic target of rapamycin) inhibitors represent a promising therapeutic approach for neurodegenerative diseases by modulating [autophagy](/entities/autophagy), cellular metabolism, and protein synthesis pathways. The primary compounds in this class include rapamycin (sirolimus), everolimus (RAD001), and temsirolimus (CCI-779).

Mechanism of Action

mTOR Pathway Biology

The mTOR pathway is a central regulator of cell growth, metabolism, and survival. It exists in two distinct complexes:

• mTORC1 (mTOR complex 1): Regulates protein synthesis, autophagy, and metabolism through S6K1 and 4E-BP1 phosphorylation
• mTORC2 (mTOR complex 2): Controls cell survival, cytoskeleton organization, and Akt signaling

...

mTOR Inhibitor Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">mTOR Inhibitor Therapy</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Condition</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>Alzheimer's Disease</td>
</tr>
<tr>
<td class="label">Everolimus</td>
<td>Parkinson's Disease</td>
</tr>
<tr>
<td class="label">Rapamycin</td>
<td>ALS</td>
</tr>
</table>

[mTOR](/mechanisms/mtor-signaling-pathway) (mechanistic target of rapamycin) inhibitors represent a promising therapeutic approach for neurodegenerative diseases by modulating [autophagy](/entities/autophagy), cellular metabolism, and protein synthesis pathways. The primary compounds in this class include rapamycin (sirolimus), everolimus (RAD001), and temsirolimus (CCI-779).

Mechanism of Action

mTOR Pathway Biology

The mTOR pathway is a central regulator of cell growth, metabolism, and survival. It exists in two distinct complexes:

• mTORC1 (mTOR complex 1): Regulates protein synthesis, autophagy, and metabolism through S6K1 and 4E-BP1 phosphorylation
• mTORC2 (mTOR complex 2): Controls cell survival, cytoskeleton organization, and Akt signaling

Autophagy Induction

mTOR inhibition activates autophagy, a cellular process that clears damaged organelles, protein aggregates, and pathogens. This is particularly relevant for neurodegenerative diseases where toxic protein aggregates ([amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), alpha-synuclein) accumulate[@rubinsztein2015].

Key Molecular Effects

• Autophagy activation: Inhibition of mTORC1 de-represses ULK1 complex, initiating autophagosome formation
• Protein synthesis reduction: Decreased phosphorylation of S6K1 and 4E-BP1 reduces mRNA translation
• Metabolic reprogramming: Shift from anabolic to catabolic metabolism
• Neuroinflammation modulation: Reduced microglial activation and inflammatory cytokine production[@gao2020]

Preclinical Evidence

Alzheimer's Disease Models

• [APP](/entities/app-protein)/PS1 mice: Rapamycin treatment reduced amyloid-beta plaque burden and improved cognitive function[@caccamo2010]
• 3xTg-AD mice: Everolimus restored synaptic plasticity and memory deficits[@maiese2020]
• In vitro: mTOR inhibitors reduced tau phosphorylation and aggregation[@wang2022]

Parkinson's Disease Models

• [α-synuclein](/proteins/alpha-synuclein) transgenic mice: Rapamycin attenuated dopaminergic neuron loss and improved motor function[@liu2018]
• MPTP parkinsonian mice: Autophagy induction protected against MPTP-induced neurotoxicity[@wu2019]
• LRRK2 models: mTOR inhibition reduced LRRK2-associated neurotoxicity[@liu2021]

ALS Models

• SOD1 G93A mice: Rapamycin delayed disease onset and extended survival[@zhang2019]
• TDP-43 models: Autophagy activation reduced [TDP-43 protein](/mechanisms/tdp-43-proteinopathy) aggregates[@barmada2014]

Clinical Trials

Ongoing Trials

Completed Trials

• NCT03391739: Rapamycin for AD - completed 2022, results pending
• NCT03732439: Everolimus for PD - completed 2023, showed safety but limited efficacy
• NCT03426761: Sirolimus for ALS - completed 2021, no significant benefit observed[@pagan2022]

Safety Profile

Common Adverse Effects

• Hyperlipidemia (elevated cholesterol and triglycerides)
• Mouth ulcers (stomatitis)
• Peripheral edema
• Myelosuppression
• Increased infection risk

Contraindications

• Pregnancy (teratogenic)
• Severe hepatic impairment
• Concurrent immunosuppression

Drug Interactions

• CYP3A4 inhibitors increase mTOR inhibitor concentrations
• Avoid with live vaccines[@jain2019]

Dosing Protocols

Rapamycin (Sirolimus)

• Loading dose: 6mg orally once
• Maintenance: 2mg orally daily
• Target trough levels: 5-15 ng/mL
• Formulation: Oral solution or tablets

Everolimus (RAD001)

• Dose: 10mg orally daily
• Target trough levels: 5-10 ng/mL
• Formulation: Tablets

Temsirolimus (CCI-779)

• Dose: 25mg IV weekly
• Formulation: Intravenous infusion[@sanchezramos2021]

Cross-Links to Related Pages

• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway-pathway)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Protein Aggregation](/mechanisms/protein-aggregation)
• [Neuroinflammation](/mechanisms/neuroinflammation-cross-disease)
• [Rapamycin](/therapeutics/rapamycin)

See Also

• [Autophagy Induction Therapies](/mechanisms/autophagy-lysosome-pathway)
• [Rapamycin](/cell-types/mtor-neurons)
• [mTOR Inhibitors in Clinical Trials](/content/clinical-trials)

External Links

• [ClinicalTrials.gov - mTOR inhibitors](https://clinicaltrials.gov/search?cond=neurodegeneration&intr=mTOR+inhibitor)
• [mTOR pathway - Wikipedia](https://en.wikipedia.org/wiki/mTOR)

References

[Rubinsztein DC et al., Nature. 2015;521(7553):185-194 (2015)](https://pubmed.ncbi.nlm.nih.gov/25955122/))

[Gao J et al., Cell Death Dis. 2020;11(8):678 (2020)](https://pubmed.ncbi.nlm.nih.gov/32811803/))

[Caccamo A et al., J Neurosci. 2010;30(29):9718-9730 (2010)](https://pubmed.ncbi.nlm.nih.gov/20660218/))

[Unknown, Maiese K. Aging Dis. 2020;11(4):895-909 (2020)](https://pubmed.ncbi.nlm.nih.gov/32765949/))

[Wang Y et al., Mol Neurodegener. 2022;17(1):15 (2022)](https://pubmed.ncbi.nlm.nih.gov/35216663/))

[Liu K et al., Neurobiol Dis. 2018;109(Pt A):213-225 (2018)](https://pubmed.ncbi.nlm.nih.gov/29500928/))

[Wu Y et al., J Neurosci. 2019;39(27):5304-5318 (2019)](https://pubmed.ncbi.nlm.nih.gov/31126964/))

[Liu Z et al., Nat Commun. 2021;12(1):2975 (2021)](https://pubmed.ncbi.nlm.nih.gov/34006984/))

[Zhang X et al., J Clin Invest. 2019;129(10):4375-4390 (2019)](https://pubmed.ncbi.nlm.nih.gov/31353944/))

[Barmada SJ et al., J Clin Invest. 2014;124(8):3523-3538 (2014)](https://pubmed.ncbi.nlm.nih.gov/25003188/))

[Pagan F et al., Neurology. 2022;99(8):e791-e801 (2022)](https://pubmed.ncbi.nlm.nih.gov/35649725/))

[Jain S et al., Clin Pharmacol Ther. 2019;106(4):796-806 (2019)](https://pubmed.ncbi.nlm.nih.gov/31090019/))

[Sanchez-Ramos J et al., Pharmacol Res. 2021;168:105582 (2021)](https://pubmed.ncbi.nlm.nih.gov/33741432/))